2 active not recruiting, 2 recruiting, 1 completed. 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Completed 1 |
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
Follow Darovasertib: new trials by email Literature Review of Darovasertib trials Research Report on Darovasertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma Darovasertib, Crizotinib (Xalkori) - Uveal Melanoma | Phase 3 | Recruiting | IDEAYA Biosciences | 450 | 2026-09-04 | 2026-11-12 |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma Darovasertib, Primary Local Therapy - Uveal Melanoma | Phase 3 | Recruiting | IDEAYA Biosciences | 520 | 2026-01-25 | 2026-05-06 |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma IDE196, Crizotinib, Pembrolizumab - Metastatic Uveal Melanoma | Phase 2 / Phase 3 | Active not recruiting | IDEAYA Biosciences | 420 | 2023-10-31 | 2026-02-17 |
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma Darovasertib - Uveal Melanoma | Phase 2 | Active not recruiting | IDEAYA Biosciences | 160 | 2023-07-03 | 2026-03-16 |
| Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma Darovasertib - Ocular Melanoma | Phase 2 | Completed | St Vincent's Hospital, Sydney | 15 | 2022-05-03 | 2026-04-23 |
Uveal Melanoma (5) · Melanoma (2) · Plaque, Amyloid (1)
IDEAYA Biosciences (4) · St Vincent's Hospital, Sydney (1)
Australia (5) · Canada (4) · United States (4) · France (3) · Germany (3) · Israel (3) · Italy (3) · Netherlands (3) · Switzerland (3) · United Kingdom (3) · Belgium (2) · Poland (2) · Spain (2) · Austria (1) · Czechia (1)
Anthony Joshua, FRACP, MBBS, PhD (1) · Hetal Patel, MD, MSHS, CHCQM (1) · Jasgit Sachdev, MD (1)